98215-44-2

Basic information

• Product Name: 3-Thiophenecarbonyl chloride, 5-bromo-
• CAS NO: 98215-44-2
• Molecular Formula: C5H2BrClOS
• Molecular Weight: 225.493
• Mol File: 98215-44-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 3-Thiophenecarbonyl chloride, 5-bromo-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Thiophenecarbonyl chloride, 5-bromo-(98215-44-2)
• EPA Substance Registry System: 3-Thiophenecarbonyl chloride, 5-bromo-(98215-44-2)

Safety Data

• Hazardous Substances Data: 98215-44-2(Hazardous Substances Data)

Upstream product

• 100523-84-0 2-bromothiophene-4-carboxylic acid 

Downstream Products

• 1461640-05-0 5-bromo-N-(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-22-0 N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-20-8 N,5-bis(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-26-4 N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-24-2 N,5-bis(3-hydroxyphenyl)-N-methylthiophene-3-carboxamide 
• 98215-51-1 5-Bromo-thiophene-3-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide 

Relevant articles and documents

Synthesis and antitumour activity of new derivatives of flavone-8- acetic acid (FAA). Part 31): 2-Heteroaryl derivatives

A range of 14 derivatives of flavone-8-acetic acid (FAA) with a heterocyclic substituent in place of the 2-phenyl group have been prepared and their anti-tumour activity evaluated in vitro against a panel of human and murine tumour cell lines and in vivo against MAC 15A. Some of the compounds, notably 2c,d and s, showed significant in vivo activity and these require further studies in order to evaluate their potential for development.

Substituted thiophene compound Preparation method and application thereof (by machine translation)

The invention relates to a thiophene compound represented by general formula I, a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the thiophene compound and application thereof. The thiophene compound and a pharmaceutically acceptable salt thereof are taken as a novel estrogen-related receptor α (ERR RR) inverse agonist. These compounds can be used to treat diseases associated with ERR and ERR RR, such as cancer, osteoporosis, diabetes, anti-aging, slimming, and the like. After further optimization and screening, the drug is expected to be developed into novel drugs for preventing and treating tumors or other ERR RR related diseases. (by machine translation)

Synthesis, Nicotinic Acetylcholine Receptor Binding, and in Vitro and in Vivo Pharmacological Properties of 2′-Fluoro-(substituted thiophenyl)deschloroepibatidine Analogues

The synthesis, nAChR in vitro and in vivo pharmacological properties of 2′-fluoro-3′-(substituted thiophenyl)deschloroepibatidine analogues (5a-f, 6a-d, and 7a-c) are presented herein. All had subnanomolar affinity at α4β2*-nAChRs. Contrary to lead structure epibatidine, a potent nAChR agonist, all were potent α4β2- and α3β4-AChR antagonists in an in vitro functional assay. In vivo, the compounds were also nAChR antagonists with various degrees of agonist activity. Compounds 5e, 5f, 6a, 6c, 6d, and 7c had no agonist effects in the tail-flick, hot-plate, hypothermia, or spontaneous activity tests, whereas 5a-d, 7a and 7b did not have agonist activity in the tail-flick and hot-plate tests but, like varenicline, were agonists in the hypothermia and spontaneous activity tests. Compound 6b had agonist activity in all four in vivo tests. All the compounds were antagonists of nicotine-induced antinociception in the tail-flick test, and all except 5c, 5d, 5f, and 6b were antagonists of nicotine-induced antinociception in the hot-plate test. Compound 7c, which had a Ki = 0.86 nM in the binding assay similar potency at α4β2/α3β4 with selectivity relative to α7 nAChRs, had an AD50 value of 0.001 μg/kg in the tail-flick test with no agonist activity in the in vitro or in vivo test had one of the more interesting profiles.